Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients

Autor: Eloisa Jantus-Lewintre, Carlos Camps, Vega Iranzo, Sara Blasco, Ana Blasco, Roy M. Bremnes, Rafael Sirera, Alfonso Berrocal, Miquel Taron, Nieves del Pozo, Rafael Rosell, Cristina Caballero
Rok vydání: 2010
Předmět:
Drug dose regimen
Male
Cancer Research
Lung Neoplasms
Unclassified drug
DNA Repair
medicine.medical_treatment
Docetaxel
NSCLC
XRCC3 protein
Treatment response
Gastroenterology
Efficacy
Efficacy to therapy
Advanced disease
Xeroderma pigmentosum group D protein 23
Multiple cycle treatment
Carcinoma
Non-Small-Cell Lung
Antineoplastic Combined Chemotherapy Protocols
Medicine
Overall survival
Hazard ratio
Middle Aged
Excision repair cross complementing protein 1
Prognosis
DNA-Binding Proteins
Survival Rate
Treatment Outcome
Oncology
Lung non small cell cancer
Drug dose reduction
Carcinoma
Squamous Cell
Female
Taxoids
medicine.drug
Human
Pulmonary and Respiratory Medicine
Adult
medicine.medical_specialty
Neutropenia
SNP
DNA repair
Adenocarcinoma
Article
Xeroderma pigmentosum group D protein 10
Internal medicine
Advanced cancer
Xeroderma pigmentosum group D protein
Chemotherapy
Humans
Lung cancer
Survival rate
Drug induced disease
Aged
Neoplasm Staging
Retrospective Studies
Xeroderma Pigmentosum Group D Protein
Chemotherapy induced neutropenia
Polymorphism
Genetic
business.industry
Retrospective cohort study
MICROBIOLOGIA
medicine.disease
Sex difference
Endonucleases
Gene frequency
Surgery
Cancer combination chemotherapy
Single nucleotide polymorphism
Drug efficacy
Carcinoma
Large Cell
Cisplatin
business
Follow-Up Studies
Zdroj: RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
instname
ISSN: 1938-0690
Popis: [EN] Background: Platinum doublets are standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). The aim of this study was to assess whether neutropenia is: (1) an indicator for treatment efficacy, or (2) associated with specific polymorphisms. Patients and Methods: Four hundred ninety-four patients, treated with cisplatin-docetaxel were retrospectively analyzed. Relative dose intensity (RDI) was assessed for both drugs. Neutrophil counts were assessed only on Day 21 of each cycle. Genotyping was performed for 4 different polymorphisms in ERCC1, XRCC3, XPD-23, and XPD-10. Results: The median overall survival was 9 months. The mean RDI was 0.94 for cisplatin and 0.93 for docetaxel. Four hundred three patients received ¿ 3 cycles of chemotherapy, and 239 received ¿ 6 cycles. Thirty-one percent developed neutropenia, and 19% had Grade (G)3-4 neutropenia. RDI was lower in patients with neutropenia (G1-4; 0.87-0.93) when compared with those without (G0; 0.94-0.95; P
Databáze: OpenAIRE
Externí odkaz: